Advanced search    

Search: authors:"Xianying Pan"

3 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

Mardekian, Cristina Masseria, Hemant Phatak. Formal analysis: Xianying Pan, Hugh Kawabata. Methodology: Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian. Writing ± original draft: Gregory Y. H ... . Lip, Shital Kamble, Hemant Phatak. Writing ± review & editing: Gregory Y. H. Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Hemant Phatak. 10 / 11 1. Hansen ML

Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach

. Lip, Steve Deitelzweig. Formal analysis: Allison Keshishian, Melissa Hamilton, Ruslan Horblyuk, Kiran Gupta, Xuemei Luo, Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Gregory Y. H. Lip ... , Jack Mardekian, Keith Friend, Anagha Nadkarni, Xianying Pan, Gregory Y. H. Lip, Steve Deitelzweig. 16 / 18 10. 11. 17 / 18 Lip GY, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, et al. Real

Comparison of costs and discharge outcomes for patients hospitalized for ischemic or hemorrhagic stroke with or without atrial fibrillation in the United States

This retrospective analysis investigated the impact of baseline clinical characteristics, including atrial fibrillation (AF), on hospital discharge status (to home or continuing care), mortality, length of hospital stay, and treatment costs in patients hospitalized for stroke. The analysis included adult patients hospitalized with a primary diagnosis of ischemic or hemorrhagic...